To demonstrate in patients with T2DM and dyslipidemia not appropriately controlled with a statin and receiving metformin, the superiority of a fixed combination of fenofibrate and metformin vs metformin alone on TG and additionally, if the superiority on TG is established, to demonstrate the superiority on HDL-C
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
482
F80mg/M500mg - per os - twice a day during 24 weeks / or / F80mg/M850mg - per os - twice a day during 24 weeks /or / F54mg/M850mg - per os - three times a day during 24 weeks
500mg - per os - twice a day during 24 weeks /or / 850mg - per os - twice a day during 24 weeks /or / 850mg - per os - three times a day during 24 weeks
TG / HDL-C ratio
Time frame: 24 weeks
Lipid and glycemic parameters
Time frame: 24 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
C LF23-0121 06 01 Site107
Brno, Czechia
C LF23-0121 06 01 Site108
Holešov, Czechia
C LF23-0121 06 01 Site101
Karlovy Vary, Czechia
C LF23-0121 06 01 Site106
Olomouc, Czechia
C LF23-0121 06 01 Site109
Olomouc, Czechia
C LF23-0121 06 01 Site103
Pardubice, Czechia
C LF23-0121 06 01 Site102
Prague, Czechia
C LF23-0121 06 01 Site104
Prague, Czechia
C LF23-0121 06 01 Site105
Prague, Czechia
C LF23-0121 06 01 Site 204
Bailleul, France
...and 60 more locations